1. Home
  2. RDVT vs LXRX Comparison

RDVT vs LXRX Comparison

Compare RDVT & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Red Violet Inc.

RDVT

Red Violet Inc.

N/A

Current Price

$40.52

Market Cap

564.8M

Sector

Technology

ML Signal

N/A

LXRX

Lexicon Pharmaceuticals Inc.

N/A

Current Price

$1.70

Market Cap

547.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RDVT
LXRX
Founded
2017
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
564.8M
547.4M
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
RDVT
LXRX
Price
$40.52
$1.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$62.00
$4.15
AVG Volume (30 Days)
81.9K
2.3M
Earning Date
06-09-2026
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
82.00
77.78
EPS
0.91
N/A
Revenue
$90,252,000.00
$49,803,000.00
Revenue This Year
$14.77
N/A
Revenue Next Year
$14.48
$22.16
P/E Ratio
$47.49
N/A
Revenue Growth
20.03
60.24
52 Week Low
$32.23
$0.32
52 Week High
$64.14
$1.83

Technical Indicators

Market Signals
Indicator
RDVT
LXRX
Relative Strength Index (RSI) 38.31 63.28
Support Level $39.89 $1.08
Resistance Level $52.21 $1.83
Average True Range (ATR) 2.38 0.12
MACD 0.18 0.02
Stochastic Oscillator 8.50 75.34

Price Performance

Historical Comparison
RDVT
LXRX

About RDVT Red Violet Inc.

Red Violet Inc is a software and services company. It specializes in data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: